{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:23:33Z","timestamp":1767914613828,"version":"3.49.0"},"reference-count":17,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2022,1,29]]},"DOI":"10.1536\/ihj.21-497","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T22:11:49Z","timestamp":1643407909000},"page":"99-105","source":"Crossref","is-referenced-by-count":5,"title":["Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension"],"prefix":"10.1536","volume":"63","author":[{"given":"Masaru","family":"Hatano","sequence":"first","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohtaro","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyushu University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuoka University Nishijin Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"GSK K.K, Medical Division"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"Tunmer","sequence":"additional","affiliation":[{"name":"GSK, Brentford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G","family":"Kiely","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fukuda K, Date H, Doi S, <i>et al<\/i>. Guidelines for the treatment of pulmonary hypertension (JCS 2017\/JPCPHS 2017). Circ J 2019; 83: 842-945.","DOI":"10.1253\/circj.CJ-66-0158"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gali\u00e8 N, Humbert M, Vachiery JL, <i>et al<\/i>. ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903-75.","DOI":"10.1183\/13993003.01032-2015"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Naeije R, Manes A. The right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2014; 23: 476-87.","DOI":"10.1183\/09059180.00007414"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. D&apos;Alonzo GE, Barst RJ, Ayres SM, <i>et al<\/i>. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-9.","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gali\u00e8 N, Channick RN, Frantz RP, <i>et al<\/i>. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53.","DOI":"10.1183\/13993003.01889-2018"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gali\u00e8 N, Barber\u00e0 JA, Frost AE, <i>et al<\/i>. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834-44.","DOI":"10.1056\/NEJMoa1413687"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sitbon O, Sattler C, Bertoletti L, <i>et al<\/i>. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J 2016; 47: 1727-36.","DOI":"10.1183\/13993003.02043-2015"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tamura Y, Kumamaru H, Satoh T, <i>et al<\/i>. Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension. Circ J 2017; 82: 275-82.","DOI":"10.1253\/circj.CJ-17-0139"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hoeper MM, McLaughlin VV, Barber\u00e0 JA, <i>et al<\/i>. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med 2016; 4: 894-901.","DOI":"10.1016\/S2213-2600(16)30307-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Maron BA, Waxman AB, Opotowsky AR, <i>et al<\/i>. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 2013; 112: 720-5.","DOI":"10.1016\/j.amjcard.2013.04.051"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. McLaughlin VV, Vachiery JL, Oudiz RJ, <i>et al<\/i>. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: results from the AMBITION trial. J Heart Lung Transplant 2019; 38: 1286-95.","DOI":"10.1016\/j.healun.2019.09.010"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. White RJ, Vonk-Noordegraaf A, Rosenkranz S, <i>et al<\/i>. Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. Respir Res 2019; 20: 208.","DOI":"10.1186\/s12931-019-1180-1"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Gabler NB, French B, Strom BL, <i>et al<\/i>. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 2012; 141: 20-6.","DOI":"10.1378\/chest.11-0404"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Preston IR, Sagliani KD, Warburton RR, Hill NS, Fanburg BL, Jaffe IZ. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2013; 304: L678-88.","DOI":"10.1152\/ajplung.00300.2012"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Maron BA, Leopold JA, Hemnes AR. Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension. Br J Pharmacol 2020; 177: 1457-71.","DOI":"10.1111\/bph.14968"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Xu W, Koeck T, Lara AR, <i>et al<\/i>. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A 2007; 104: 1342-7.","DOI":"10.1073\/pnas.0605080104"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Vachi\u00e9ry JL, Tedford RJ, Rosenkranz S, <i>et al<\/i>. Pulmonary hypertension due to left heart disease. Eur Respir J 2019; 53: 30545974.","DOI":"10.1183\/13993003.01897-2018"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/1\/63_21-497\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T03:44:04Z","timestamp":1643427844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/1\/63_21-497\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.21-497","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"article-number":"21-497"}}